464 related articles for article (PubMed ID: 30568030)
1. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.
Johnson DB; Nixon MJ; Wang Y; Wang DY; Castellanos E; Estrada MV; Ericsson-Gonzalez PI; Cote CH; Salgado R; Sanchez V; Dean PT; Opalenik SR; Schreeder DM; Rimm DL; Kim JY; Bordeaux J; Loi S; Horn L; Sanders ME; Ferrell PB; Xu Y; Sosman JA; Davis RS; Balko JM
JCI Insight; 2018 Dec; 3(24):. PubMed ID: 30568030
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of HLA-II related to LAG-3
Guo W; Peng D; Liao Y; Lou L; Guo M; Li C; Yu W; Tian X; Wang G; Lv P; Zuo J; Shen H; Li Y
Cancer Sci; 2024 May; 115(5):1388-1404. PubMed ID: 38480275
[TBL] [Abstract][Full Text] [Related]
3. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.
Wang J; Sanmamed MF; Datar I; Su TT; Ji L; Sun J; Chen L; Chen Y; Zhu G; Yin W; Zheng L; Zhou T; Badri T; Yao S; Zhu S; Boto A; Sznol M; Melero I; Vignali DAA; Schalper K; Chen L
Cell; 2019 Jan; 176(1-2):334-347.e12. PubMed ID: 30580966
[TBL] [Abstract][Full Text] [Related]
4. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
5. Comment on "Cutting edge: FcR-like 6 is an MHC class II receptor".
Huard B
J Immunol; 2010 Nov; 185(9):4965; author reply 4965-6. PubMed ID: 20962262
[No Abstract] [Full Text] [Related]
6. The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth.
McCaw TR; Li M; Starenki D; Cooper SJ; Liu M; Meza-Perez S; Arend RC; Buchsbaum DJ; Forero A; Randall TD
Cancer Immunol Immunother; 2019 Feb; 68(2):175-188. PubMed ID: 30334128
[TBL] [Abstract][Full Text] [Related]
7. LAG-3 inhibits the activation of CD4
Maruhashi T; Okazaki IM; Sugiura D; Takahashi S; Maeda TK; Shimizu K; Okazaki T
Nat Immunol; 2018 Dec; 19(12):1415-1426. PubMed ID: 30349037
[TBL] [Abstract][Full Text] [Related]
8. Regulation of expression of the human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II.
Bruniquel D; Borie N; Hannier S; Triebel F
Immunogenetics; 1998 Jul; 48(2):116-24. PubMed ID: 9634475
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human
Burova E; Hermann A; Dai J; Ullman E; Halasz G; Potocky T; Hong S; Liu M; Allbritton O; Woodruff A; Pei J; Rafique A; Poueymirou W; Martin J; MacDonald D; Olson WC; Murphy A; Ioffe E; Thurston G; Mohrs M
Mol Cancer Ther; 2019 Nov; 18(11):2051-2062. PubMed ID: 31395688
[TBL] [Abstract][Full Text] [Related]
10. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
Dempke WCM; Fenchel K; Uciechowski P; Dale SP
Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
[TBL] [Abstract][Full Text] [Related]
11. The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes.
Hannier S; Triebel F
Int Immunol; 1999 Nov; 11(11):1745-52. PubMed ID: 10545478
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands.
Garman B; Jiang C; Daouti S; Kumar S; Mehta P; Jacques MK; Menard L; Manjarrez-Orduno N; Dolfi S; Mukherjee P; Rai SC; Lako A; Koenitzer JD; David JM
Front Immunol; 2023; 14():1151748. PubMed ID: 37795090
[TBL] [Abstract][Full Text] [Related]
13. The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukaemias blast cells HLA-DR expression.
Antohe I; Tanasa MP; Dăscălescu A; Dănăilă C; Titieanu A; Zlei M; Ivanov I; Sireteanu A; Cianga P
Immunobiology; 2021 Jan; 226(1):152049. PubMed ID: 33352400
[TBL] [Abstract][Full Text] [Related]
14. Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice.
Foy SP; Sennino B; dela Cruz T; Cote JJ; Gordon EJ; Kemp F; Xavier V; Franzusoff A; Rountree RB; Mandl SJ
PLoS One; 2016; 11(2):e0150084. PubMed ID: 26910562
[TBL] [Abstract][Full Text] [Related]
15. Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia.
Shapiro M; Herishanu Y; Katz BZ; Dezorella N; Sun C; Kay S; Polliack A; Avivi I; Wiestner A; Perry C
Haematologica; 2017 May; 102(5):874-882. PubMed ID: 28154084
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein.
Huard B; Mastrangeli R; Prigent P; Bruniquel D; Donini S; El-Tayar N; Maigret B; Dréano M; Triebel F
Proc Natl Acad Sci U S A; 1997 May; 94(11):5744-9. PubMed ID: 9159144
[TBL] [Abstract][Full Text] [Related]
17. Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression.
Pinton L; Solito S; Damuzzo V; Francescato S; Pozzuoli A; Berizzi A; Mocellin S; Rossi CR; Bronte V; Mandruzzato S
Oncotarget; 2016 Jan; 7(2):1168-84. PubMed ID: 26700461
[TBL] [Abstract][Full Text] [Related]
18. The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma.
Nagasaki J; Togashi Y; Sugawara T; Itami M; Yamauchi N; Yuda J; Sugano M; Ohara Y; Minami Y; Nakamae H; Hino M; Takeuchi M; Nishikawa H
Blood Adv; 2020 Sep; 4(17):4069-4082. PubMed ID: 32870971
[TBL] [Abstract][Full Text] [Related]
19. Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer-T cell coculture models.
Mimura K; Kua LF; Xiao JF; Asuncion BR; Nakayama Y; Syn N; Fazreen Z; Soong R; Kono K; Yong WP
Gastric Cancer; 2021 May; 24(3):611-623. PubMed ID: 33611641
[TBL] [Abstract][Full Text] [Related]
20. Roles of lymphatic endothelial cells expressing peripheral tissue antigens in CD4 T-cell tolerance induction.
Rouhani SJ; Eccles JD; Riccardi P; Peske JD; Tewalt EF; Cohen JN; Liblau R; Mäkinen T; Engelhard VH
Nat Commun; 2015 Apr; 6():6771. PubMed ID: 25857745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
